Cabilatazan, Ricky C.

HRN: 25-51-26  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/22/2024
CEFUROXIME 750MG (VIAL)
08/22/2024
08/28/2024
IV
750mg
TID
Infected Wound PAOD
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Bone & JointSkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: